
## Vitor Trovisco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11189924/publications.pdf Version: 2024-02-01



VITOR TROVISCO

#	Article	IF	CITATIONS
1	Harmonizing model organism data in the Alliance of Genome Resources. Genetics, 2022, 220, .	2.9	52
2	FlyBase: updates to the <i>Drosophila melanogaster</i> knowledge base. Nucleic Acids Research, 2021, 49, D899-D907.	14.5	374
3	The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Research, 2021, 49, D325-D334.	14.5	2,416
4	FlyBase 2.0: the next generation. Nucleic Acids Research, 2019, 47, D759-D765.	14.5	697
5	Analysis of the expression patterns, subcellular localisations and interaction partners of <i>Drosophila</i> proteins using a <i>pigP</i> protein trap library. Development (Cambridge), 2014, 141, 3994-4005.	2.5	160
6	Oskar Is Targeted for Degradation by the Sequential Action of Par-1, GSK-3, and the SCF-Slimb Ubiquitin Ligase. Developmental Cell, 2013, 26, 303-314.	7.0	21
7	In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine-Related Cancer, 2011, 18, 401-412.	3.1	11
8	Germline variation of the melanocortinâ€l receptor does not explain shared risk for melanoma and thyroid cancer. Experimental Dermatology, 2009, 18, 548-552.	2.9	4
9	Acquisition of <i>BRAF</i> gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clinical Endocrinology, 2008, 69, 683-685.	2.4	27
10	Intragenic Mutations in Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 333-362.	3.2	87
11	Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines. Thyroid, 2007, 17, 707-715.	4.5	81
12	Molecular genetics of papillary thyroid carcinoma: great expectations Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 643-653.	1.3	28
13	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Human Pathology, 2006, 37, 562-568.	2.0	26
14	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Human Pathology, 2006, 37, 781-786.	2.0	72
15	Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109, 207-210.	7.7	85
16	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 589-595.	2.8	242
17	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Human Pathology, 2005, 36, 694-697.	2.0	93
18	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2005, 230, 149-150.	7.2	4

VITOR TROVISCO

#	Article	IF	CITATIONS
19	BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 572-6.	2.8	108
20	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology, 2004, 202, 247-251.	4.5	334
21	BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	3.6	171
22	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 2003, 22, 4578-4580.	5.9	616